Skip to main content
. 2014 Jun 18;23(1):21–28. doi: 10.1007/s00520-014-2309-x

Table 1.

Participant and disease characteristics

Category France Germany UK
(n = 159) (n = 166) (n = 159)
(%) (%) (%)
Gender
 Female 46.8 62.0 56.6
 Male 53.2 38.0 43.4
Age
  < 45 years 37.2 58.0 42.8
 46–65 years of age 44.2 32.9 37.0
  > 65 years 18.6 9.1 20.2
Primary cancer types
 Breast 36.1 23.2 36.5
 Lung 20.9 20.7 13.2
 Prostate 14.6 17.7 21.4
 Kidney 8.2 7.9 4.4
 Colon 6.3 7.9 5.0
 Thyroid 2.5 4.3 5.0
 Melanoma 1.9 4.3 3.1
 Other 9.5 14.0 11.3
Time since primary cancer diagnosis
 < 2 years 69.1 79.5 67.8
Time since bone metastases diagnosis
 < 1 year 73.0 67.2 65.4
Among those currently taking treatment to delay complications of bone metastases 68.4 75.8 70.9
 Oral (pills or tablets) 22.7 32.2 30.8
 Intravenously 67.3 46.2 51.5
 Subcutaneously 9.1 20.3 13.8
Currently receiving chemotherapy 73.0 68.5 53.5
Among those currently receiving chemotherapy: How is chemotherapy given
 Intravenously 80.9 67.3 63.1
 Oral (pills and tablets) 17.4 26.5 32.1
 Other 1.7 6.2 4.8
Losing ability to move around affected the patient the most in the past 2 weeks 30.6 46.7 53.5
Had a complication because of bone metastases 50.9 57.4 59.5
Severity of worst pain in the past week for any reason
 No pain 1.9 1.8 5.7
 Mild 9.4 22.4 28.9
 Moderate 45.3 50.3 44.7
 Severe 43.4 25.5 20.8
Severity of average pain in the past week for any reason
 No pain 2.5 3.0 6.3
 Mild 19.0 29.9 32.3
 Moderate 64.6 51.2 53.2
 Severe 13.9 15.9 18.2